"Exanthema" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.
| Descriptor ID |
D005076
|
| MeSH Number(s) |
C17.800.257
|
| Concept/Terms |
Exanthema- Exanthema
- Skin Rash
- Rash, Skin
- Rash
- Exanthem
|
Below are MeSH descriptors whose meaning is more general than "Exanthema".
Below are MeSH descriptors whose meaning is more specific than "Exanthema".
This graph shows the total number of publications written about "Exanthema" by people in this website by year, and whether "Exanthema" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 3 | 3 |
| 2020 | 4 | 1 | 5 |
| 2021 | 1 | 3 | 4 |
| 2022 | 3 | 0 | 3 |
| 2023 | 4 | 0 | 4 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Exanthema" by people in Profiles.
-
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy. J Immunother Cancer. 2024 Apr 10; 12(4).
-
Neonate With a Diffuse Maculopapular and Nodular Rash. Neoreviews. 2024 Apr 01; 25(4):e232-e236.
-
Neonate With a Diffuse Maculopapular and Nodular Rash. Neoreviews. 2024 Apr 01; 25(4):e232-e236.
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
-
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. Oncoimmunology. 2024; 13(1):2290787.
-
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer. 2024 Jan; 196:113458.
-
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer. 2024 03 15; 130(6):876-885.
-
What Came First: Malnutrition or Severe Disease? Pediatrics. 2023 09 01; 152(3).
-
Immunopathogenic Insights on Preferential Human Herpesvirus-6 Reactivation in Drug Rash With Eosinophilia and Systemic Symptoms: A Scoping Review. J Cutan Med Surg. 2023 Jul-Aug; 27(4):388-398.
-
Respiratory Distress and Macular Rash in a 13-year-old Girl. Pediatr Rev. 2023 03 01; 44(3):165-169.